About Pharmazz
Pharmazz is a Healthcare company based in Noida (India) founded in 2010 by Ajit Chand Srimal and Anil Gulati. It operates as a clinical stage company developing critical care medicines. Pharmazz has raised $57.02 million across 18 funding rounds from investors including Sun Pharma, HHS and Duke Fashions. The company has 37 employees. Pharmazz was last valued at $38.86 million in March 2020. Its chief executive is Anil Gulati. Its Indian entity Pharmazz India Private Limited reported revenue of ₹18.18 Cr. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals and 5 more; 2 of its 10 listed competitors have raised funding.
Company details
Pharmazz is a clinical stage pharmaceutical company engaged in the development of pharmaceutical products for use in critical care and hospital settings. The company has three lead candidates, PMZ-2010 (for hypovolemic shock, cardiac arrest postoperative pain), PMZ-1620 ( for Alzheimers, ischemic stroke, spinal cord injury and tumor diagnosis) and PMZ-2123 (for opioid tolerance pain management, diabetic ketoacidosis. These molecules are in preclinical different clinical stages for different indications. The company also provides pre-clinical and clinical services to other pharmaceutical companies.
- Headquarters Noida, India
- Employees 37
- Founders Ajit Chand Srimal, Anil Gulati
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pharmazz.com
- Social LinkedIn X Facebook Instagram
- Legal Name Pharmazz India Private Limited
- Date of Incorporation 16 Mar, 2011
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹18.18 Cr
FY 2024 · +138% YoY
- Net Profit₹3.53 Cr
FY 2024 · 19% margin
- EBITDA₹8.03 Cr
FY 2024 · 44% margin
- Total Equity Funding$57.02M (USD)
in 18 rounds
- Latest Funding Round$250K (USD), Series C
Jul 2026
- InvestorsSun Pharma
& 97 more
- Employee Count37
Associated legal entities of Pharmazz
Pharmazz operates through Pharmazz India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pharmazz India Private Limited CIN U24100DL2011FTC215954 | Active | 16 Mar 2011 | New Delhi, Delhi | ₹18.2 Cr | 37 | 5 | View details |
Funding Insights of Pharmazz
Pharmazz has successfully raised a total of $57.02M across 18 strategic funding rounds. The most recent funding activity was a Series C round of $250 thousand completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.02M
- Total Rounds 18
- Last Round Series C — $250,000
- First Round $1.32M
(Dec 2013)
- Investors Count 98
Latest 10 of 18 funding rounds of Pharmazz with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $250,000 | Series C | – | – | – |
| Jul 2026 | $250,000 | Series C | – | – | – |
| May 2025 | $25M | Series C | – | – | |
| Aug 2024 | $15M | Series B | – | Sun Pharma | – |
| Feb 2024 | $150,000 | Series A | – | – | – |
| Jun 2023 | $5.45M | Debt – Conventional | – | – | – |
| Oct 2022 | $2.3M | Series A | – | – | – |
| Oct 2021 | $1.21M | Series A | – | – | |
| Apr 2021 | $250,000 | Series A | – | – | – |
| Mar 2020 | $1.41M | Series A | $38.86M | Shubham Bajaj |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2020 | $38.86M | •••••••• |
| Aug 2019 | $39.12M | •••••••• |
| Feb 2019 | $••••• | •••••••• |
| May 2015 | $••••• | •••••••• |
| Dec 2013 | $••••• | •••••••• |
Full valuation and stage history of Pharmazz
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $38.86M (Mar 2020). 98 investors in total: 10 institutional and 88 angel.
Investors in Pharmazz
Pharmazz has secured backing from 98 investors, including institutional and angel investors. Prominent investors backing the company include Sun Pharma, HHS and Duke Fashions.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India | |
- | – | ajitenterprises.tcc.mode | - | |
Internet first brand of moderate casual wear for men and women | 1966 | dukeindia.com | Ludhiana, India | |
- | – | ajitenterprises.com | - | |
Distribution and provision of audio-visual and technology solutions in India. | 2011 | univesointegration.com | Delhi, India | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | sabarinternational.com | - | |
- | – | sabarinternational.tcc.mode | - | |
Wholesale supplier of men's big and tall clothing in various styles. | 1985 | dukeclothing.com | Nottingham, United Kingdom | |
- | – | gcjsharebrokers.tcc.mode | - |
Investor details for Pharmazz
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Pharmazz India Private Limited (Pharmazz)
Pharmazz India Private Limited is the primary company behind Pharmazz. The board of Pharmazz India Private Limited currently have 5 directors; the longest-serving is Anil Gulati, appointed in 2011. 7 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anil Gulati DIN 00454517 | Director | 16 Mar 2011 | 15 yrs 7 mo | Pharmazz India Private Limited |
| Sunil Gulati DIN 00034538 | Director | 16 Mar 2011 | 15 yrs 7 mo | Pharmazz India Private Limited |
| Lov Verma DIN 07560071 | Director | 04 Feb 2017 | 9 yrs 8 mo | Pharmazz India Private Limited |
| Manish Subhashrao Lavhale DIN 09278455 | Managing Director | 14 Aug 2021 | 5 yrs 2 mo | Pharmazz India Private Limited |
| Dharmesh Kiritkumar Shah DIN 11393190 | Additional Director | 24 Nov 2025 | 10 mo | Pharmazz India Private Limited |
People of Pharmazz
20 people are tracked at Pharmazz (7 in leadership, 9 in board & advisors, 4 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership | |
| Co-Founder & CEO | Leadership | |
Guru Reddy | Executive Vice President | Leadership |
| Chief Operating Officer | Leadership | |
| Managing Director, India | Leadership | |
Vineet Bajaj | Director, Accounting & Finance | Leadership |
David Costello | VP & Controller | Leadership |
Jane Kiernan | Advisor | Board & advisors |
Ashish K. Khanna | Advisor | Board & advisors |
Ravi Kant | Advisor | Board & advisors |
James Ford Mcdonnell | Director | Board & advisors |
Anthony Davenport | Advisor | Board & advisors |
Shridhar Andurkar | Advisor | Board & advisors |
R. C. Srimal | Advisor | Board & advisors |
| Director | Board & advisors | |
Neil Marwah | Director | Board & advisors |
Sachin Shukla | National Sales Manager | Team |
Amit khasat | Scientific sales manager | Team |
Bhavana Sengar | Deputy Manager - HR & Operations | Team |
Mrityunjay Singh | IT Manager | Team |
Complete people profiles for Pharmazz
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Pharmazz
Figures of Pharmazz India Private Limited, the primary company behind Pharmazz, for FY 2024. Revenue was ₹18.18 Cr (+138% year on year). Net profit was ₹3.53 Cr (19% margin). EBITDA was ₹8.03 Cr (44% margin). Revenue has grown at a compounded annual rate of +257% over three years and +195% over five years.
- ₹18.18 CrRevenue · FY 2024 · +138% YoY
- ₹3.53 CrNet profit · 19% margin
- ₹8.03 CrEBITDA · 44% margin
- ₹4.81 CrPaid-up capital
- 37Employees (provident fund records)
- +257%Revenue CAGR, 3 years
- +195%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pharmazz India Private Limited are on its company page.
Detailed financial statements for Pharmazz
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pharmazz
4 dated milestones of Pharmazz across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Pharmazz is founded.
- Funding First funding round of $1.3M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series C, of $250K.
Competitors of Pharmazz
Pharmazz has 10 listed competitors in our database, 2 of them funded. They include Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. |
Detailed competitors of Pharmazz
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pharmazz
The website of Pharmazz (pharmazz.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 6.8% vs previous month
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Pharmazz (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pharmazz
Complete news archive for Pharmazz
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmazz
Pharmazz was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Pharmazz is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.
Anil Gulati is the current CEO of Pharmazz. They have also founded this company.
Pharmazz is a funded company, having raised a total of $57.02M across 18 funding rounds to date. The company's 1st funding round was a Series A of $1.41M, raised on Dec 2013.
Pharmazz has 37 employees.
The primary company behind Pharmazz, Pharmazz India Private Limited, reported revenue of ₹18.18 Cr for FY 2024, up 138% year on year.
Pharmazz is a clinical stage pharmaceutical company engaged in the development of pharmaceutical products for use in critical care and hospital settings. The company has three lead candidates, PMZ-2010 (for hypovolemic shock, cardiac arrest postoperative pain), PMZ-1620 ( for Alzheimers, ischemic stroke, spinal cord injury and tumor diagnosis) and PMZ-2123 (for opioid tolerance pain management, diabetic ketoacidosis. These molecules are in preclinical different clinical stages for different indications. The company also provides pre-clinical and clinical services to other pharmaceutical companies.
Pharmazz's top competitors include Merck, Roivant Sciences and AbbVie.
Pharmazz has 98 investors. Key investors include Sun Pharma, HHS, Duke Fashions, Univeso Integrated Solutions, and Lalit Gulati.
The valuation of Pharmazz is $38.86M as of Mar 2020.
Pharmazz operates through Pharmazz India Private Limited.
The legal entities of Pharmazz currently have 5 directors, including Anil Gulati, Sunil Gulati, Lov Verma and others.